Kyntra Bio, Inc.

What they do

Kyntra Bio develops FG-3246, a fully human antibody-drug conjugate targeting CD46, for metastatic castration-resistant prostate cancer (mCRPC), along with the companion PET imaging agent FG-3180; a Phase 2 monotherapy dose optimization study began in Q3 2025. The company also holds retained rights to roxadustat in the U.S., Canada, Mexico and other markets outside AstraZeneca's and Astellas's territories, while Astellas commercializes roxadustat (EVRENZO) in Europe and Japan. In August 2025 the company closed the sale of its China operations to AstraZeneca Treasury Limited for $220.4 million, comprising $85.0 million enterprise value and $135.4 million net cash held in China.

Revenue drivers

• Roxadustat (EVRENZO) royalties and collaboration revenue — Roxadustat is approved in Europe, Japan, China and numerous other countries for anemia in chronic kidney disease; Astellas commercializes it in Europe and Japan, and Kyntra retains U.S., Canada and Mexico rights, generating partnership revenue.
• FG-3246 and FG-3180 clinical-stage pipeline — No product revenue yet; the CD46-targeting ADC and its PET imaging agent are in a Phase 2 mCRPC trial, and the company is exploring development of roxadustat in lower-risk MDS with high transfusion burden.
• China operations (divested August 2025) — The company sold its China business, including FibroGen Beijing and its 51.1% interest in Falikang, to AstraZeneca for $220.4 million total consideration, removing that revenue stream going forward.

Recent performance

Total revenue from continuing operations in Q2 2026 was $(1.5) million, compared to $1.3 million in Q2 2025. Net income from continuing operations was $12.0 million, or $2.96 per basic and diluted share, versus a net loss of $13.7 million, or $3.38 per share, a year earlier. Full-year 2025 revenue was $6.4 million with net income of $183.5 million and diluted EPS of $45.37, reflecting the gain on the China divestiture. Recent quarterly revenue has been volatile: $1.1 million in Q3 2025, $1.3 million in Q4 2025, $3.7 million in Q1 2026 and $(1.5) million in Q2 2026. As of June 30, 2026, cash, cash equivalents, investments and accounts receivable totaled $95.7 million.

Strategy

Kyntra Bio is advancing FG-3246 through a Phase 2 monotherapy dose optimization study in mCRPC, with an interim analysis targeted for Q4 2026. The company finalized the Phase 3 protocol for roxadustat in lower-risk MDS with high transfusion burden and aims to initiate the registrational study in Q4 2026, either internally or with a strategic partner. Additional Phase 3 MATTERHORN data presented at EHA Congress 2026 showed improvements in transfusion independence in HTB patients regardless of ring sideroblast status. In January 2026 the company rebranded from FibroGen to Kyntra Bio and began trading on Nasdaq under KYNB, framing the change as a step in its transformation toward oncology and rare disease assets.

Risks

• Dependence on lead programs — The company states it is substantially dependent on the success of roxadustat and FG-3246 (with FG-3180), so failure in either program could materially and adversely affect the business.
• Regulatory approval uncertainty — Drug development and marketing authorization are difficult, and the company may ultimately be unable to obtain approval for its product candidates in one or more jurisdictions or indications.
• Negative shareholder equity — At June 30, 2026, total liabilities of $109.2 million exceeded total assets of $101.1 million, leaving shareholder equity of negative $30.1 million.
• Listing-rule failure — The company reported a delisting notice or listing-rule failure in an 8-K filed April 9, 2026.

Outlook

Management expects an interim analysis of the Phase 2 FG-3246 trial in mCRPC in Q4 2026. The company also aims to initiate the registrational Phase 3 trial of roxadustat in lower-risk MDS with high transfusion burden in Q4 2026. Kyntra Bio states it expects its cash, cash equivalents, investments and accounts receivable to be sufficient to fund operating plans into 2028.